WO2001002031A3 - Targeted anticalcification treatment - Google Patents
Targeted anticalcification treatment Download PDFInfo
- Publication number
- WO2001002031A3 WO2001002031A3 PCT/US2000/017606 US0017606W WO0102031A3 WO 2001002031 A3 WO2001002031 A3 WO 2001002031A3 US 0017606 W US0017606 W US 0017606W WO 0102031 A3 WO0102031 A3 WO 0102031A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- treatments
- targeted agents
- targeted
- calcification
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000012620 biological material Substances 0.000 abstract 2
- 230000002308 calcification Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 abstract 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004792 oxidative damage Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Methods for providing biomaterials with increased resistance to calcification by treating with cell-targeted agents and/or with matrix-targeted agents. Cell-targeted agents are used which block calcium channels or which prevent oxidative damage to cells and/or inhibit enzymes. Other treatments of biomaterials may remove cell-derived calcium-binding components or target extracellular matrices, as by cleaving proteins with cyanogen bromide or reducing disulfide bonds to produce sulfhydryl groups which are thereafter alkylated. Combinations of the foregoing different treatments are also effective in increasing the calcification resistance of cardiovascular tissues that were previously subjected to chemical fixing and/or other anticalcification treatments.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56397/00A AU5639700A (en) | 1999-07-01 | 2000-06-27 | Targeted anticalcification treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14217199P | 1999-07-01 | 1999-07-01 | |
US60/142,171 | 1999-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001002031A2 WO2001002031A2 (en) | 2001-01-11 |
WO2001002031A3 true WO2001002031A3 (en) | 2001-12-06 |
Family
ID=22498818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/017606 WO2001002031A2 (en) | 1999-07-01 | 2000-06-27 | Targeted anticalcification treatment |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5639700A (en) |
WO (1) | WO2001002031A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8900294B2 (en) | 2002-01-04 | 2014-12-02 | Colibri Heart Valve Llc | Method of controlled release of a percutaneous replacement heart valve |
US9119738B2 (en) | 2010-06-28 | 2015-09-01 | Colibri Heart Valve Llc | Method and apparatus for the endoluminal delivery of intravascular devices |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078163B2 (en) | 2001-03-30 | 2006-07-18 | Medtronic, Inc. | Process for reducing mineralization of tissue used in transplantation |
US7955788B2 (en) | 2003-10-30 | 2011-06-07 | Medtronic, Inc. | Bioprosthetic tissue preparation with synthetic hydrogels |
SG191008A1 (en) | 2010-12-14 | 2013-07-31 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets |
RU2597564C1 (en) * | 2015-06-17 | 2016-09-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) | Method for prediction of risk of calcification of biological prostheses of cardiac valves |
WO2019051476A1 (en) | 2017-09-11 | 2019-03-14 | Incubar, LLC | Conduit vascular implant sealing device for reducing endoleak |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753652A (en) * | 1984-05-04 | 1988-06-28 | Children's Medical Center Corporation | Biomaterial implants which resist calcification |
EP0564786A2 (en) * | 1992-02-12 | 1993-10-13 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
WO1996013227A1 (en) * | 1994-10-21 | 1996-05-09 | University Of Michigan | Calcification-resistant bioprosthetic tissue and methods of making same |
US5558875A (en) * | 1994-06-06 | 1996-09-24 | Wang; Su | Method of preparing collagenous tissue |
US5843182A (en) * | 1994-03-14 | 1998-12-01 | Cryolife, Inc. | Treated tissue for implantation and methods of preparation |
-
2000
- 2000-06-27 WO PCT/US2000/017606 patent/WO2001002031A2/en active Application Filing
- 2000-06-27 AU AU56397/00A patent/AU5639700A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753652A (en) * | 1984-05-04 | 1988-06-28 | Children's Medical Center Corporation | Biomaterial implants which resist calcification |
EP0564786A2 (en) * | 1992-02-12 | 1993-10-13 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5843182A (en) * | 1994-03-14 | 1998-12-01 | Cryolife, Inc. | Treated tissue for implantation and methods of preparation |
US5558875A (en) * | 1994-06-06 | 1996-09-24 | Wang; Su | Method of preparing collagenous tissue |
WO1996013227A1 (en) * | 1994-10-21 | 1996-05-09 | University Of Michigan | Calcification-resistant bioprosthetic tissue and methods of making same |
Non-Patent Citations (1)
Title |
---|
HENRY P D: "ANTI-ATHEROSCLEROTIC EFFECTS OF CALCIUM ANTAGONISTS: A BRIEF REVIEW", CLINICAL AND INVESTIGATIVE MEDICINE, vol. 10, no. 6, 1 November 1987 (1987-11-01), pages 601 - 605, XP000604021 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8900294B2 (en) | 2002-01-04 | 2014-12-02 | Colibri Heart Valve Llc | Method of controlled release of a percutaneous replacement heart valve |
US9125739B2 (en) | 2002-01-04 | 2015-09-08 | Colibri Heart Valve Llc | Percutaneous replacement heart valve and a delivery and implantation system |
US9186248B2 (en) | 2002-01-04 | 2015-11-17 | Colibri Heart Valve Llc | Percutaneously implantable replacement heart valve device and method of making same |
US9554898B2 (en) | 2002-01-04 | 2017-01-31 | Colibri Heart Valve Llc | Percutaneous prosthetic heart valve |
US9119738B2 (en) | 2010-06-28 | 2015-09-01 | Colibri Heart Valve Llc | Method and apparatus for the endoluminal delivery of intravascular devices |
Also Published As
Publication number | Publication date |
---|---|
AU5639700A (en) | 2001-01-22 |
WO2001002031A2 (en) | 2001-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1101801A (en) | Compositions for treating shoes and methods and articles employing same | |
WO2004031350A3 (en) | Modulation of forkhead box o1a expression | |
ATE347277T1 (en) | COMPOSITION HAVING BACTERIOSTATIC AND BACTERICIDAL PROPERTIES AGAINST BACTERIAL SPORES AND CELLS AND METHOD FOR USE THEREOF FOR TREATING FOOD | |
DE60231395D1 (en) | DECELLULARIZATION OF TISSUE MATRIXES | |
IL73533A (en) | Enzyme-resistant immunomodulatory peptides,and their preparation | |
WO2006121518A3 (en) | Electrical devices, anti-scarring agents, and therapeutic compositions | |
IL160188A0 (en) | Materials and methods to promote repair of nerve tissue | |
WO2002103103A3 (en) | Fluorine-containing compounds and polymers derived therefrom | |
CA2387198A1 (en) | Method for treating hair loss using thyromimetic compounds | |
TR200201250T2 (en) | Hydroxyiecosatetraenoate salts, their compositions and methods for their use in the treatment of dry eye disorders. | |
WO2001002031A3 (en) | Targeted anticalcification treatment | |
AU5638200A (en) | Tissue products having antiviral properties | |
WO2002030357A3 (en) | Compounds and methods for modulating ccr4 function | |
WO2002089730A3 (en) | Compounds and methods for the modulation of cd154 | |
PT1537274E (en) | ENZYME PRESS FELT TREATMENT | |
UA94231C2 (en) | Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm | |
IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
MX2010003349A (en) | Method of using composite enzyme for degumming jute (1). | |
CY1112119T1 (en) | METHOD FOR COATING COATING | |
WO2003012031A3 (en) | Antisense modulation of stearoyl-coa desaturase expression | |
WO2001084937A8 (en) | Oxidoreductase mediated antimicrobial activity | |
PT1092040E (en) | METHODS OF INHIBIT HELICOBACTER PYLORI | |
AU2002233951A1 (en) | Compositions for pre-treating shoes and methods and articles employing same | |
WO2001056593A3 (en) | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke | |
AP9801416A0 (en) | Method Of treating a plant disease. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |